Skip to main content
S 3051 106th Congress Senate Health Administrative procedure Commerce Department of Health and Human Services Drug approvals Drug industry Generic drugs Government Operations and Politics Intellectual property Law Patents Pharmaceutical research Prescription pricing Right of petition Science, Technology, Communications

GAAP Act of 2000

Introduced: September 14, 2000 Introduced by: Schumer, Charles E. Democratic · New York See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 106th Congress ended
It never became law before the 106th Congress (1999–2000) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Sep 14, 2000
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S8590)
Sep 14, 2000
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service
Greater Access to Affordable Pharmaceuticals Act or GAAP Act of 2000 - Amends the Federal Food, Drug, and Cosmetic Act to include in a required abbreviated new drug application information concerning certification of each patent which claims any active ingredient for a listed drug (currently, only the listed drug itself), either alone or in combination with other active ingredients, or which claims the first approved use for such drug for which an applicant is seeking approval.

States that the filing of a citizen petition review shall not cause the Secretary of Health and Human Services to delay review and approval of an abbreviated new drug application unless the petition demonstrates through substantial scientific proof that approval would pose a threat to public health and safety.

Allows a drug to be considered a bioequivalent to a listed drug if the effects of such drug and the listed drug do not show a significant difference based on certain tests or studies.

Provides for an accelerated date of approval of a generic drug application.

Expresses the sense of Congress that measures should be taken to effectuate the purpose of the Drug Price Competition and Patent Term Restoration Act of 1984 to make generic drugs more available and accessible, thereby reducing health care costs.

What's happening now September 14, 2000

Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S8590)

 Related & companion bills 1
  • HR 5247 Identical bill GAAP Act of 2000
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). S. 3051: GAAP Act of 2000. 106th Congress. Open America. https://openamerica.io/bill/106-S-3051/
MLA
"S. 3051: GAAP Act of 2000." 106th Congress, 2026, Open America, https://openamerica.io/bill/106-S-3051/.
Bluebook (legal)
S. 3051, 106th Cong. (2026), https://openamerica.io/bill/106-S-3051/.
Markdown link
[S. 3051: GAAP Act of 2000](https://openamerica.io/bill/106-S-3051/)
Report a problem